Expert Guidance for the Treatment of Myelofibrosis
Expert Guidance for the Treatment of Myelofibrosis

Released: May 08, 2023

Instructions

This Interactive Decision Support Tool provides treatment recommendations from 5 experts based on the specific patient and disease characteristics you enter in the tool. It is recommended that you have as much information as possible available before you begin.

You will be prompted to provide specific information about your patient, including the presence of MF symptoms, splenomegaly, or anemia; platelet count; prognostic risk group; and previous JAK inhibitor therapy.

Click on your selections. Your choices can be changed at any time simply by selecting the [change] icon by the question you want to change and entering a new choice.

Additional information on each variable/characteristic and why it is important for making management decisions is available by clicking on the [i] icon after each selection.

When all patient characteristics are entered, you will be asked to select the management option you are currently planning. Once that information is entered, you can click on Submit Patient Case to view the expert recommendations.

After reviewing your case-specific recommendations, you will be asked brief questions about how the recommendations influenced your decision-making. You will then be able to enter a new case scenario by clicking the Start New Case button.

When viewing the tool on the CCO website, you also will have the following options:

  • Print/download the recommendations along with a summary of the patient characteristics and selected therapy you entered by clicking the Case Summary button
  • View an Additional Considerations section covering additional factors that may affect choice of therapy in myelofibrosis and future directions in the management of this disease

Access to and use of this Interactive Decision Support Tool titled, “Expert Guidance for the Treatment of Myelofibrosis” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices for patients with myelofibrosis. The information provided is based on the expert guidance of Prithviraj Bose, MD; John Mascarenhas, MD; Ruben A. Mesa, MD, FACP; Raajit Rampal, MD, PhD; and Brady L. Stein, MD, MHS.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Expert Guidance for the Treatment of Myelofibrosis” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights, are disclaimed.

Any trademarks are the property of respective companies.

© 2023 Clinical Care Options, LLC. All rights reserved.

Program Content